The MS Challenge
Multiple Sclerosis (MS) is a disabling autoimmune disease that affects the central nervous system (CNS). MS is characterized by chronic inflammation resulting in damage to both the brain and retina.
• Most people are diagnosed between the ages of 20-40 years old
• 1 million cases in the United States (200 new cases each week)
• 2.5 million cases in the world
Relapsing-Remitting (RRMS) patients experience highly unpredictable symptom flare-ups and, without effective treatment, ultimately transition to secondary-progressive MS (SPMS), with symptoms worsening more steadily over time and for which there are currently no FDA-approved therapies.
Physicians monitor MS disease progress and treatment efficacy by reviewing patients’ symptoms and conducting MRI exams every 6-12 months. As a result, new inflammatory activity in the CNS can go undetected for months, preventing early intervention. Early detection of disease activity and proper treatment of RRMS is crucial to reducing the risk of disease progression and accrual of disability.
There is a critical need for a device that enables MS patients to monitor their disease activity and treatment response between follow-up visits.
JuneBrain is currently developing solutions to address this need.
Our technology is currently patent pending.